Outcome of Board Meeting

Date: July 27, 2026 To, To, Sr. General Manager Sr. General Manager BSE Limited National Stock Exchange of India Limited Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Sub.: Outcome of Board Meeting of the Company held on Monday, July 27, 2026 Dear Sir/Madam, In compliance with Regulations 30, 33, and 47 read with Schedule III and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting held today i.e., M1.o nUdnaay,u Jduiltye 2d7 F, i2n0a2n6c, ihaal sR ienstuerlt-as loiaf, tahpep Croovmedp athney following: Unaudited Consolidated and Standalone Financial Results of the Company for the quarter ended June 30, 2026, together with the Limited Review Report thereon; Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, the Company hereby con�irms and declares that M/s. Pankaj R. Shah and Associates, Chartered Accountants (Firm Registration No. 107361W), Statutory Auditors of the Company have issued their Limited Review Reports on the Unaudited Consolidated and Standalone Financial Results of the Company for the quarter ended June 30, 2026. Annexure-A. The �inancial results along with the reports of the auditors of the Company are enclosed herewith Mase dia Release Annexure -B. in relation to the Unaudited Consolidated and Standalone �inancial results of the 2. CCohmanpgaen yin f otrh eth See qnuiaorrt eMra ennadgeedm Juennet 3P0e,r 2s0o2n6n,e isl (e“nScMloPs”e)d o hfe trheew Citohm apsany Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (ListingObligations and Disclosure Requirements), Regulations, 2015, as amended from time to time, we wish to inform you that the Board, on recommendation of the Nomination and Remuneration Committee, approved the appointment and categorization of Ms. Anjali Shah, Assistant Vice President-Finance as Senior Management Personnel (“SMP”) of the Company with effect from July 27, 2026. Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 The details as required pursuant to Regulation 30 of Securities and Exchange Board of IndAinan (eLxisutirneg- COb ligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the Kindly note that the meeting of Board of Directors of the Company commenced at 01:45 P.M. (IST) and concluded at 02:55 P.M. (IST). This intimation and aforesaid information are also being uploaded on the Company’s website at www.senorespharma.com. You are requested to take the same on record. TFohra nSkeinnogr yeosu P. harmaceuticals Limited Deval Rajnikant Shah Whole Time Director & CFO DIN: 00332722 Enclosures: As above Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Annexure - A PankRa.Sjh a&h Associates ContinuatSihoene t CharterAecdc ountants Wec onduocutrree dv ioeftw h set ateimnae cncto rdwainttchheS e t andoanRr edv iEenwg agement (SRE2)4 1"0R,e vioefIw n teFriinma nicnifaolr mpaetrifoonbr ymte hdIe n depeAnuddeinottfto hre Entiitsys"ub eytd h Ien stoiftC uhtaer tAecrceodu notfaI nntdTsih ai.ss t andraerqdu tihraewtsep lan anpde rftohrreme viteoow b tamiond eraastseu raasnt cowe h etthheferi nansctaitaelm aerfnert eosef matemriisaslt atAe rmeevnite.w ipsr ilmiatmroiii ntlqeyud io rfci oemsp apneyr soannndae nla lytical procedauprpelsti oef di nandcaitaaanl dt hupsr ovliedseas s suratnhcaaenn a udWieth .a vneo t perfoarnma eudda intad c cdoirngwledy o,n oetx praensa su doipti nion. Thea ccompasntyaitnegm iennctlsuu dneasu dited intreersiuomlf 4t ssfu ibnsaindcaiinaad3rl i es Stepdsouwbns idiinacrliuiednse sdtt haet ewmheonstu,en audiintteedfr iinma rnecsiuarllet fslt eoctta l revenRuse.s1 81C.r1o9rt eost,na elpt r oaffittte arox f R s3.1 .2C2r oraensdt otcaolm prehensive incoimsRe s 3.1 .c2r2o rfeotsrh qeu aretnedre3 d01� J un2e0,2 r6e specatsic voenlsyi,di entr heed respeccotnisvoel iudnaatuedfdii tneadnr ceisauTllh tessu.en audiintteedfr iinma nrceisauollft t hsi s subsihdaisba ereyrn e viebwyte hde aiurd iatnodrh sa vbee eanp proavnedfd u rnitsouh seb dyt he managemaennodtu c ro nciloounns t he staitnse ofm aearnsi t rt,e lattote hsae m ounatnsdd i sclosures incluidnre eds poeftc htsi usb sidiisba arsyes,do loenls yu cuhn audiintteedfr iinma nrceisaualln tds informOautcrio onnc.l uinssoi mtoo nd ifiinre eds poeftc htmi ast ter. Baseodno urre viceown duacsta ebdo vneo,t hhiancsgo mteoo uart tentthicaoatnu suests o b elieve thatth aec compaSntyaitnegm pernetp,ai rnae cdc ordwainttchhe re e cognaintdmi eoans urement princliapidldoe wsin n I ndiAacnc ounSttianngd (a"Ir ndAd S "a)s s peciufnideeSdre ct1i3o3no f CompanAicet2s,0 1a3s a mendreeda,wd i trhe lervualnietss s utehdeu rned aenrdo threerc ognized accounptriancgta incdpe osl ihcainseo sdt i scltohsieen df ormraetqiuotinorb eedd i sclionts eerdom fs thRee gularteiawodin t,th h Cei rcuilnacrl utdhimena gn nienrw hiiciths t ob ed iscloorst ehdai,tt contaaniyns m amtiesrsitaalt ement. Date:27-07-2026 ForP,a nkRaS jh a&hA ssociates PlacAeh:m edabad ChartAecrceodu ntants RegistNroa.t1i0o7n3 61W CAN ileSshha h Partner MemberNsoh.i1p0 7414 UDI2N6:1 07414PGXPKX5989 SENOREPSH ARMACEUTILCIAMLIST ED RegistOefrfeid1c 1e0:t1 o1 1031,1 th SfoluotToohrw ,e OrN,E 4 2O,p posJiatayen tiPlaarAlkm ,b ali RBooapdAa,hl m ed a bad, G3u8j0a0r5a4t , India, CINL:2 4290GJ2017PLIWC e1b0s0i2wwt6we3.: s eneoshrparma.IcP ohmo ne+:9 1-27999-998JE5 -7m acisl@:s enpohreasrma.com StatemoefnU tn audiCtoends olidFaitneadn cRieaslu lftostr h eQ uarteenrd eJdu ne3 0,2026 (Rsi.nC rores) FoQru aretnedre d Yeaern ded SrN o. Particulars Jun3e0 ,2 026M arc3h1, 2 026J un3e0 2,0 25M arc3h1, 2 026 UnauditedA udited Unaudited Audited 1 RevenFureoO mp erations 180.21 175.19 132.56 632.63 2 OthIenrc ome 2.81 17.67 8.79 47.06 3 TotIanlc ome 183.02 192.86 141.35 679.69 4 Expenses Cosotfm atercioanlssu med 31.15 27.05 29.38 114.27 Purchoafss etso ck-in-trade 34.01 35.71 27.55 137.32 Changienis n ventooff riineigsso hoeddws o,r k-in-apnrdo gsrteoscsk -in-tr0a.d5e6 3.46 4.43 0.07 Emplobyeenee fits expenses 29.91 30.32 21.65 112.25 Finacnocset s 7.17 8.46 5.04 25.03 Deprec&iA amtoirotni esxapteinosne s 9.94 9.30 5.99 31.25 Otheexrp enses 30.82 31.16 20.81 100.40 Toteaxlp enses 143.56 145.46 114.86 520.59 5 Probfietf oTraex 39.46 47.40 26.49 159.10 6 Taexx pense Currteanxt 9.82 (4.97) 4.91 19.94 Defertraexd (0.81) 15.70 0.40 17.63 TotTaalxE xpense 9.01 10.73 5.31 37.57 7 NetP roaffittte arx 30.45 36.67 21.18 121.53 8 OthCeorm preheInnsciovIm(e eL oss) A( iI)t etmhswa itnl olbt e r eclasssuibfsieeqdut eop nrtoolfrlyi o ts s 0.00 0.24 - (0.02) (ii) tIanrxce olmateto ii tnegm s tnhobatet r ewcillalst sopi rfoaifneilddt o ss - (0.08) (0.01) B( iI)t etmhswa itbl elr eclasssuibfsieeqdut oep nrtoolfrlyi o ts s 0.51 41.76 0.47 29.22 (iIin)c otmaerx e lattoii tnegtm hswa itbl elr eclastsopi rfoaifneilddto ss - - - TotOatlh Ceorm preheInnsciovIm(e eL oss) 0.51 41.92 0.47 29.19 9 TotCaolm preheInnsciovmee 30.96 78.59 21.65 150.72 10 Proffoitrth pee riaotdt ribtuot able EquHiotlyd oeftr hsCe o mpany 30.72 31.61 19.73 115.38 NonC otnrolIlnitnegr ests (0.27) 5.06 1.45 6.16 OthCeorm preheInnsciovamete t ribtuot able Equity oHfto hlCedo emrp [Showing first 8,000 characters — download PDF for full document]